Long-term survival following hematopoietic stem cell transplantation (HSCT) is dependent not only on eradication of primary disease but on the rapid restoration of durable hematopoiesis and immune competence. Despite more precise HLA typing, novel cytoreductive regimens, and improved methods to detect and treat opportunistic pathogens, infection, with or without GVHD, remains the primary cause of transplant mortality in patients lacking an HLA-matched sibling. The purpose of this core is to provide a centralized program to monitor the effect of transplant regimen, donor type and stem cell source on the quality of the graft infused, degree of donor/host chimerism, disease recurrence, and the kinetics of immunologic reconstitution. Stem cell grafts will be analyzed for degree and quality of T-cell depletion, nucleated and CD34+ cell dose, and progenitor cell content. The regenerating marrow and circulating lymphoid cells will be assessed for chimerism by minisatellite PCR analysis or FISH. The effect of adoptive immunotherapy for the treatment of EBV-LPD, relapse of CML or WT1 positive leukemia will be assessed by detection of EBV genome, BCR-ABL, and/or WT1 transcripts, respectively. The quality and tempo of immunologic reconstitution will be analyzed longitudinally by assessment of the phenotype and function (proliferation, cytotoxicity, antibody production) of the circulating lymphoid populations and correlated with recovery of serum insulin-like growth factor levels, T-cell receptor excision circle (TREC) positive cells, and infectious complications. These studies should help to gauge the effects of stem cell source (PBSC versus BM), donor selection (HLA-matched related, mis-matched related, or unrelated), use and/or method of T-cell depletion, intensity of cytoreduction (ablative or non-ablative), and immunomodulatory agents (recombinant growth hormone, interleukin-7, viral and/or tumor specific-CTLs) on the most common transplant related complications, namely relapse, regimen related toxicity, and infection.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA023766-24A1
Application #
6591047
Study Section
Project Start
2002-05-08
Project End
2003-02-28
Budget Start
Budget End
Support Year
24
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 39:222-239
Lin, Richard J; Ho, Caleb; Hilden, Patrick D et al. (2018) Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol :
Malard, Florent; Labopin, Myriam; Cho, Christina et al. (2018) Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol 11:127
Luduec, Jean-BenoƮt Le; Kudva, Anupa; Boudreau, Jeanette E et al. (2018) Novel multiplex PCR-SSP method for centromeric KIR allele discrimination. Sci Rep 8:14853
Shah, Gunjan L; Moskowitz, Craig H (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689-1697
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Velardi, Enrico; Tsai, Jennifer J; Radtke, Stefan et al. (2018) Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. Nat Med 24:239-246
Moskowitz, Craig H (2018) Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2:821-824
Kim, Seong Jin; Huang, Yao-Ting; Foldi, Julia et al. (2018) Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. Transpl Infect Dis 20:e12881

Showing the most recent 10 out of 452 publications